|
Market Closed -
Nasdaq
23:00:00 04/09/2026 +03
|
After hours 02:19:19 | |||
| 29.66 USD | +0.68% |
|
30.18 | +1.74% |
| 09-01 | Beam Therapeutics Inc. Appoints Eric Foster as Chief Commercial Officer | CI |
| 08-20 | Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder | RE |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| BEAM | Delayed | |
CBOE
| BEAM | Real-time | |
|
Mexican S.E.
| BEAM * | End-of-day quote |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Neutral |
| Resistance | 31.03 | 37.92 | 34.81 |
| Spread/Res. | -4.42% | -21.78% | -14.79% |
| Spread/Supp. | +4.62% | +35.43% | +36.56% |
| Support | 28.35 | 21.9 | 21.72 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- BEAM Stock
- Charts Beam Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
